See more : Ares Acquisition Corporation (AAC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Gilead Sciences, Inc. (GILD.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gilead Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Atlas Lithium Corporation (ATLX) Income Statement Analysis – Financial Results
- Zegona Communications plc (ZEG.L) Income Statement Analysis – Financial Results
- Xinyi Solar Holdings Limited (XISHY) Income Statement Analysis – Financial Results
- Regenx Tech Corp. (RGXTF) Income Statement Analysis – Financial Results
- Blackhawk Growth Corp. (BLRZF) Income Statement Analysis – Financial Results
Gilead Sciences, Inc. (GILD.SW)
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.31B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B | 11.20B | 9.70B | 8.39B | 7.95B | 7.01B | 5.34B | 4.23B | 3.03B | 2.03B | 1.32B | 867.86M | 466.79M | 233.77M | 195.56M | 169.00M | 32.60M | 40.00M | 33.40M | 2.70M | 4.10M | 4.20M | 2.80M | 1.30M |
| Cost of Revenue | 6.60B | 4.57B | 4.68B | 4.85B | 4.37B | 4.26B | 4.01B | 3.79B | 2.86B | 2.47B | 2.12B | 1.87B | 1.60B | 1.13B | 768.77M | 433.32M | 260.33M | 166.59M | 112.69M | 69.72M | 43.76M | 21.50M | 16.90M | -2.20M | -1.80M | -3.60M | -3.20M | -2.80M | -1.70M | -1.00M | -800.00K |
| Gross Profit | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B | 28.63B | 21.10B | 8.34B | 7.23B | 6.26B | 6.08B | 5.42B | 4.21B | 3.46B | 2.59B | 1.77B | 1.16B | 755.17M | 397.07M | 190.01M | 174.05M | 152.10M | 34.80M | 41.80M | 37.00M | 5.90M | 6.90M | 5.90M | 3.80M | 2.10M |
| Gross Profit Ratio | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | 85.68% | 87.17% | 87.42% | 87.02% | 85.06% | 81.28% | 89.00% | 90.00% | 106.75% | 104.50% | 110.78% | 218.52% | 168.29% | 140.48% | 135.71% | 161.54% |
| Research & Development | 5.36B | 5.04B | 9.11B | 5.02B | 3.73B | 5.10B | 3.01B | 2.85B | 2.12B | 1.76B | 1.23B | 1.07B | 939.92M | 721.77M | 591.03M | 383.86M | 277.72M | 223.55M | 164.87M | 134.76M | 185.55M | 131.57M | 112.90M | 75.30M | 59.20M | 41.90M | 0.00 | 26.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B | 3.43B | 2.98B | 1.70B | 1.46B | 1.24B | 1.04B | 946.69M | 797.34M | 705.74M | 573.66M | 379.25M | 302.79M | 250.16M | 181.30M | 125.14M | 82.79M | 78.30M | 31.00M | 25.50M | 26.70M | 34.70M | 7.60M | 22.40M | 9.10M | 6.10M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.22M | 0.00 | 0.00 | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| Operating Expenses | 10.61B | 10.19B | 13.49B | 9.07B | 7.61B | 8.50B | 6.44B | 5.84B | 3.82B | 3.22B | 2.47B | 2.12B | 1.89B | 1.52B | 1.30B | 957.52M | 656.97M | 526.35M | 425.25M | 316.06M | 310.69M | 226.37M | 203.80M | 109.10M | 87.70M | 73.10M | 37.90M | 36.40M | 24.10M | 10.10M | 6.90M |
| Cost & Expenses | 17.21B | 14.76B | 18.16B | 13.93B | 11.98B | 12.76B | 10.45B | 9.63B | 6.68B | 5.69B | 4.60B | 3.99B | 3.48B | 2.65B | 2.07B | 1.39B | 917.30M | 692.93M | 537.94M | 385.78M | 354.46M | 247.87M | 220.70M | 106.90M | 85.90M | 69.50M | 34.70M | 33.60M | 22.40M | 9.10M | 6.10M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.58M | 60.29M | 42.40M | 59.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M | 688.00M | 412.00M | 306.89M | 360.92M | 205.42M | 108.96M | 69.66M | 12.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -792.00M | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 344.70M | 278.21M | 302.23M | 265.48M | 212.94M | 102.47M | 51.28M | 47.28M | 35.78M | 24.41M | 20.86M | 14.43M | 14.69M | 12.01M | 12.60M | 2.80M | 3.00M | 4.50M | 3.20M | 2.80M | 1.70M | 1.00M | 800.00K |
| EBITDA | 9.30B | 4.17B | 7.58B | 10.30B | 15.92B | 19.23B | 23.45B | 16.36B | 4.88B | 4.27B | 4.17B | 4.30B | 3.79B | 2.85B | 2.32B | -590.92M | 1.20B | 680.83M | -146.67M | 87.83M | 71.10M | -43.57M | -53.00M | -53.30M | -25.00M | -17.20M | -24.20M | -22.90M | -12.40M | -3.50M | -3.20M |
| EBITDA Ratio | 34.07% | 16.88% | 33.77% | 46.55% | 60.97% | 63.28% | 71.84% | 65.73% | 43.54% | 44.00% | 49.77% | 54.09% | 54.12% | 53.39% | 54.88% | -19.53% | 59.04% | 51.40% | -16.90% | 18.81% | 30.41% | -22.28% | -31.36% | -163.50% | -62.50% | -51.50% | -896.30% | -558.54% | -295.24% | -125.00% | -246.15% |
| Operating Income | 10.10B | 2.69B | 6.18B | 8.87B | 14.63B | 18.07B | 22.35B | 15.31B | 4.53B | 3.99B | 3.87B | 4.03B | 3.58B | 2.75B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 56.41M | -55.58M | -65.60M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Operating Income Ratio | 36.97% | 10.88% | 27.52% | 40.09% | 56.04% | 59.47% | 68.47% | 61.51% | 40.46% | 41.13% | 46.16% | 50.75% | 51.09% | 51.47% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.13% | -28.42% | -38.82% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| Total Other Income/Expenses | -1.82B | -1.02B | -1.02B | -1.07B | -1.10B | -977.00M | -690.00M | -454.00M | -324.42M | -378.88M | -220.00M | -120.47M | -79.83M | -12.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M | 13.67M | 0.00 | 18.40M | 18.30M | 15.00M | 5.20M | 4.20M | 4.30M | 1.90M | 800.00K |
| Income Before Tax | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B | 21.66B | 14.86B | 4.21B | 3.61B | 3.65B | 3.91B | 3.50B | 2.73B | 2.27B | -638.21M | 1.16B | 656.42M | -167.53M | 73.40M | 57.45M | -41.91M | -65.60M | -37.70M | -9.70M | -6.70M | -22.20M | -21.50M | -9.80M | -2.60M | -3.20M |
| Income Before Tax Ratio | 30.32% | 6.76% | 22.99% | 35.25% | 51.82% | 56.26% | 66.36% | 59.69% | 37.57% | 37.23% | 43.54% | 49.23% | 49.95% | 51.25% | 53.67% | -21.09% | 57.28% | 49.56% | -19.30% | 15.72% | 24.57% | -21.43% | -38.82% | -115.64% | -24.25% | -20.06% | -822.22% | -524.39% | -233.33% | -92.86% | -246.15% |
| Income Tax Expense | 2.08B | 1.58B | -204.00M | 2.34B | 8.89B | 3.61B | 3.55B | 2.80B | 1.15B | 1.04B | 861.95M | 1.02B | 876.36M | 723.25M | 655.04M | 551.75M | 347.88M | 207.05M | -95.53M | 1.30M | 4.14M | 1.20M | 900.00K | 18.40M | 18.30M | 15.00M | 5.20M | 4.20M | 4.30M | 1.90M | 800.00K |
| Net Income | 6.20B | 89.00M | 5.36B | 5.46B | 4.64B | 13.49B | 18.11B | 12.06B | 3.06B | 2.57B | 2.79B | 2.89B | 2.63B | 2.01B | 1.62B | -1.19B | 813.91M | 449.37M | -72.00M | 72.10M | 53.31M | -43.11M | -66.50M | -56.10M | -28.00M | -21.70M | -27.40M | -25.70M | -14.10M | -4.50M | -4.00M |
| Net Income Ratio | 22.71% | 0.36% | 23.89% | 24.68% | 17.79% | 44.38% | 55.47% | 48.45% | 27.29% | 26.53% | 33.26% | 36.35% | 37.45% | 37.69% | 38.19% | -39.32% | 40.13% | 33.92% | -8.30% | 15.45% | 22.81% | -22.04% | -39.35% | -172.09% | -70.00% | -64.97% | -1,014.81% | -626.83% | -335.71% | -160.71% | -307.69% |
| EPS | 5.89 | 0.07 | 4.20 | 4.17 | 3.55 | 10.07 | 12.37 | 7.92 | 2.00 | 1.70 | 1.80 | 1.69 | 1.45 | 1.09 | 0.87 | -0.65 | 0.45 | 0.26 | -0.04 | 0.05 | 0.04 | -0.03 | -0.05 | -0.06 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | 5.89 | 0.07 | 4.20 | 4.17 | 3.52 | 9.93 | 11.90 | 7.32 | 1.80 | 1.63 | 1.76 | 1.65 | 1.41 | 1.05 | 0.84 | -0.65 | 0.43 | 0.24 | -0.04 | 0.04 | 0.03 | -0.03 | -0.05 | -0.06 | -0.03 | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.05B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.51B | 1.55B | 1.71B | 1.81B | 1.84B | 1.86B | 1.84B | 1.82B | 1.73B | 1.61B | 1.56B | 1.52B | 1.46B | 1.37B | 971.62M | 938.43M | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
| Weighted Avg Shares Out (Dil) | 1.05B | 1.27B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.69B | 1.58B | 1.58B | 1.75B | 1.87B | 1.92B | 1.93B | 1.84B | 1.90B | 1.86B | 1.61B | 1.65B | 1.62B | 1.46B | 1.37B | 971.62M | 938.43M | 889.15M | 680.77M | 595.94M | 512.73M | 360.00M | 304.76M |
Source: https://incomestatements.info
Category: Stock Reports